PHAT News and Press, Phathom Pharmaceuticals Inc.

2026-03-27 13:41:28 ET More on Phathom Pharmaceuticals Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Phathom Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Phathom Pharmaceuticals, ...

2026-03-11 18:02:19 ET Phathom Pharmaceuticals, Inc. (PHAT) Barclays 28th Annual Global Healthcare Conference March 11, 2026 3:30 PM EDT... Read the full article on Seeking Alpha For further details see: Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual G...

2026-02-27 11:52:20 ET Image source: The Motley Fool. Thursday, February 26, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-26 17:10:22 ET More on Phathom Pharmaceuticals Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript Phathom: Why I'm Not Buying The Dip (Yet) Phathom Pharmaceuticals Non-GAAP EPS of -$0.08 beats by $0.11, revenue of $57.6M beats by $0.16M ...

2026-02-26 17:09:06 ET Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

2026-02-26 07:20:17 ET More on Phathom Pharmaceuticals Phathom: Why I'm Not Buying The Dip (Yet) Phathom Pharmaceuticals Q4 2025 Earnings Preview Phathom slumps 12%; prices $130M stock at $16 per share Seeking Alpha’s Quant Rating on Phathom Pharmaceut...

Over 1.1 million total VOQUEZNA ® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of appr...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-02-25 12:25:32 ET More on Phathom Pharmaceuticals Phathom: Why I'm Not Buying The Dip (Yet) Phathom slumps 12%; prices $130M stock at $16 per share Phathom Pharma plans public offering after reporting preliminary 2025 results Seeking Alpha’s Quant...

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, Fe...